Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 14/20 | 0.75 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.75 |
| ▸ | DRD3 | P35462 | 7/20 | 0.57 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354894 | 1.00 | DRD2 (0.75) | DRD2SIGMAR1DRD3HTR6SLC6A4 | |
| SCHEMBL28644153 | 0.96 | DRD2 (0.73) | DRD2SIGMAR1DRD3HTR6SLC6A4 | |
| SCHEMBL17368147 | 0.94 | DRD2 (0.67) | DRD2SIGMAR1DRD3HTR6SLC6A4 | |
| SCHEMBL17366554 | 0.92 | DRD2 (0.65) | DRD2SIGMAR1DRD3HTR6SLC6A4 | |
| SCHEMBL25690904 | 0.90 | DRD2 (0.62) | DRD2SIGMAR1DRD3HTR6SLC6A4 | |
| SCHEMBL17366553 | 0.89 | DRD2 (0.61) | DRD2SIGMAR1DRD3HTR6SLC6A4 | |
| Pridopidine SCHEMBL29664816 | 0.86 | DRD2 (1.00) | DRD2SIGMAR1DRD3HTR6SLC6A4 | |
| Pridopidine SCHEMBL166748 | 0.86 | DRD2 (1.00) | DRD2SIGMAR1DRD3HTR6SLC6A4 | |
| SCHEMBL25614171 | 0.85 | DRD2 (0.56) | DRD2SIGMAR1DRD3HTR6SLC6A4 | |
| Pridopidine SCHEMBL15007479 | 0.85 | DRD2 (0.97) | DRD2SIGMAR1DRD3HTR6SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10130621-B2 | Analogs of pridopidine, their preparation and use | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2018-11-20 | — | — | US | claimed |
| EP-4049998-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Prilenia Neurotherapeutics Ltd. (IL) | 2022-08-31 | — | — | EP | disclosed |
| EP-3160470-B1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Prilenia Neurotherapeutics Ltd (IL) | 2022-08-03 | — | — | EP | disclosed |
| EP-3325443-B1 | PROCESS FOR PREPARING PRIDOPIDINE | Prilenia Neurotherapeutics Ltd (IL) | 2022-06-08 | — | — | EP | disclosed |
| US-20220023280-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PRILENIA NEUROTHERAPEUTICS LTD. | 2022-01-27 | — | — | US | disclosed |
| US-20220023280-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PRILENIA NEUROTHERAPEUTICS LTD. | 2022-01-27 | — | — | US | disclosed |
| US-11141412-B2 | Analogs of pridopidine, their preparation and use | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2021-10-12 | — | — | US | disclosed |
| US-11141412-B2 | Analogs of pridopidine, their preparation and use | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2021-10-12 | — | — | US | disclosed |
| US-20200030308-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PRILENIA NEUROTHERAPEUTICS LTD. | 2020-01-30 | — | — | US | disclosed |
| US-20200030308-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PRILENIA NEUROTHERAPEUTICS LTD. | 2020-01-30 | — | — | US | disclosed |
| US-10130621-B2 | Analogs of pridopidine, their preparation and use | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2018-11-20 | — | — | US | disclosed |
| EP-3160470-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Teva Pharmaceutical Industries Ltd (IL) | 2017-05-03 | — | — | EP | disclosed |
| CN-106456618-A | Pridopidine analogues, their preparation and use | 泰华制药工业有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20170022158-A1 | PROCESS FOR PREPARING PRIDOPIDINE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-01-26 | — | — | US | disclosed |
| US-20170022158-A1 | PROCESS FOR PREPARING PRIDOPIDINE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-01-26 | — | — | US | disclosed |
| WO-2016003919-A8 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2017-01-26 | — | — | WO | disclosed |
| WO-2016003919-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2016-01-07 | — | — | WO | disclosed |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-12-31 | — | — | US | disclosed |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-12-31 | — | — | US | disclosed |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11141412-B2 | Analogs of pridopidine, their preparation and use | PDE7A, PDE3A, PDE4D | DRD2 7/4885SIGMAR1 267/4885DRD3 21/4885 |
| US-20170022158-A1 | PROCESS FOR PREPARING PRIDOPIDINE | PDE6D, QDPR, PDE4D | DRD2 15/4885SIGMAR1 826/4885DRD3 55/4885 |
| US-20200030308-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | QDPR, DRD2, OPRD1 | DRD2 2/4885SIGMAR1 14/4885DRD3 5/4885 |
| US-20220023280-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PDE3A, PDE4D, PDE9A | DRD2 14/4885SIGMAR1 142/4885DRD3 30/4885 |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | QDPR, DRD2, OPRD1 | DRD2 2/4885SIGMAR1 14/4885DRD3 5/4885 |
| US-10130621-B2 | Analogs of pridopidine, their preparation and use | QDPR, DRD2, OPRD1 | DRD2 2/4885SIGMAR1 14/4885DRD3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.